Channel Medsystems was founded to bring innovation to the delivery of women’s healthcare.
The Cerene device is Channel’s flagship PMA approved product and offers a differentiated treatment option for women suffering from heavy menstrual bleeding. Cerene’s safety and effectiveness is supported by significant long-term clinical data and can be performed minimally invasively in the office setting without the need for IV sedation / anesthesia. Channel’s unique value proposition positions the Company as a leader in the large and growing Women’s Health market. The Company is based in Berkeley, CA.
InnovaHealth Partners invested in Channel Medsystems in June 2021. Mortimer Berkowitz III and Richard B. Emmitt are Directors of Channel.
